GEN2 is well tolerated with minimal toxicity and signs of pharmacodynamic activity in an ongoing Phase 1 dose escalation and ...

Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to date Initiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) ...

The authors confirm that telomeres in telomerase-positive cells terminate with 5'-ATC in a Pot1-dependent manner, and demonstrate that this principle holds true in telomerase-negative ALT cells as ...

Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to dateInitiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expect ...

Gene therapy is at the cutting edge of medicine, with exciting new products being developed and used to treat a wide variety ...

Web accessibility market leader accessiBe, today, in celebration of Global Accessibility Awareness Day (GAAD), announced the launch of its first community-led product advisory board comprised of ...

a biotechnology company pioneering the development of novel genetic medicines, today announced it has secured a $5 million ...

On Tuesday, WhatsApp scored a major victory against NSO Group when a jury ordered the infamous spyware maker to pay more than $167 million in damages to the Meta-owned company. The ruling ...

This key milestone is marked as a 'game changer' by the Ploug Group at the University of Copenhagen's Biotech Research & Innovation Centre ... partially filled and full adeno-associated virus (AAV) ...

Our reputation as a growth leader in the industry is driven by our success of our powerful new logo sales engine winning ... but they jumpstart you for another vector of growth.

In the world of technology, every day, we come across multiple news stories that hit the headlines in terms of funding, ...

The approval allows the DMD gene therapy to be sold in Japan for up to seven years, but more trials will be needed for full ...